Mapi Pharma’s long-acting formulation of glatiramer acetate, GA Depot, may help stabilize disability scores over time in people with both relapsing forms of multiple sclerosis (MS) and primary progressive MS (PPMS). That’s according to new analyses of data from an open-label Phase 2a clinical trial…
Spring is finally here and it’s time to enjoy the delicious fruits available this time of year. If you’re looking for a last-minute dish that’s healthy and requires zero cooking, this fruit salad is your new go-to. It’s crisp, refreshing, and … Continue reading → Source:…
Medicaid coverage of highly effective disease-modifying therapies (DMTs) for multiple sclerosis (MS) varies across the U.S., with some states offering no access at all, a study reported. The research suggests that where a person lives could influence whether they receive high-efficacy therapies, which are known…
Tweet With Alemtuzumab about 50% of people need a thrid dose because of disease breakthrough and only about 50% of them would need a forth course because of disease breakthrough. The result is when there is disease breakthrough another dose was given. Cladribine development was…
A new method called target trial emulation (TTE) used real-world data to successfully replicate the findings of a previous clinical trial of Tecfidera (dimethyl fumarate) involving people with relapsing-remitting multiple sclerosis (RRMS), according to a study report. The approach also generated new evidence showing that…
Real-world use of Octave Bioscience’s artificial intelligence (AI)-powered blood test for classifying multiple sclerosis (MS) activity has increased substantially in the few years since its commercial U.S. launch. In clinical practice, the multiple sclerosis disease activity (MSDA) test has mainly been used for routine monitoring,…
Tweet Tolebrutinib which is a irreversible BTK inhibitor was shown in a trial to inhibit non-relapsing progressive MS, but development has been held up in US because of liver damage signals. Results from the HERCULES phase 3 study showed delay in disability progression in people…
Multiple Sclerosis explores the new pavillion Turns out, I AM a Barbie girl. If Barbie was a perpetually confused, middle aged woman with a slight attitude, MS, and a ton of fatigue. And sneakers. None of those little, pink, plastic heals for me, thank you…
First-line treatment with Ocrevus (ocrelizumab) preserved walking abilities and hand function in most people with early relapsing-remitting multiple sclerosis (RRMS) over six years, according to data from a Phase 3b clinical trial and its extension study. The findings were presented in a talk by Robert…
I had never known anyone personally who had been admitted to a psychiatric hospital. Walking my husband, Rhead, through those doors was one of the strangest moments of my life — not strange in a dramatic way, but strange in the quiet, disorienting way of…